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Complex biological pathways including angiogenesis, invasion, osteoclastic activation and bone matrix degradation are involved in the
formation of bone metastasis (BM). The aim of our study was to investigate the cross-sectional and longitudinal associations of a panel
of 12 serum biochemical markers reflecting biological pathways underlying BM development. In a cross-sectional study, we
investigated 29 patients with primary breast carcinoma without BM (BC/BM ), 28 patients with breast carcinoma and BM (BC/
BMþ) and 15 healthy women. In longitudinal analyses, we investigated 34 patients for whom serum was obtained a two different
time points: at the time of primary BC diagnosis and after a median time of 3 years. During this follow-up, 15 patients developed BM,
whereas the other 19 remained free of BM. In patients who developed BM, the second samples were obtained before BM was
documented by bone scan. The cross-sectional analyses have shown all biochemical markers to be significantly elevated in patients
with BM, when compared to the patients without BM and healthy controls, except TGFb1 that was significantly decreased.
Multivariable analyses showed that only the bone resorption markers TRACP 5b, CTX and ICTP, and the marker of angiogenesis
VEGF were independently associated with BM. Those markers correctly distinguished 85% of BC patients with or without BM from
normal individuals. Longitudinal analyses showed that patients with primary BC who developed BM during follow-up had higher levels
of TRACP5b (þ95%, P¼0.08) at the time of primary diagnosis, those patients had also a higher increases of ICTP (P¼0.006),
MMP-7 (P¼0.004) and TIMP-1 (P¼0.017) during follow-up than patients who did not progress toward bone metastasis. This study
provides evidence of increase and interrelationship of circulating markers of angiogenesis, invasion and bone resorption in patients
with BC with and without BM. Markers of bone resorption have the highest independent diagnostic value for detecting and
potentially predicting BM in breast carcinoma patients.
British Journal of Cancer (2006) 95, 506–514. doi:10.1038/sj.bjc.6603285 www.bjcancer.com
Published online 1 August 2006
& 2006 Cancer Research UK
Keywords: breast carcinoma; bone metastases; bone markers; matrix metalloproteinases; prognosis
                                                         
Bone is one of the most common sites of metastasis for certain
types of tumours, especially prostate, breast and lung carcinoma
(Mundy, 2002). Breast cancer progression to bone is a defining
feature of a highly malignant tumour and the major cause of
cancer-treatment failure. Early detection of bone metastasis is
critical for clinical management and accurate staging of tumours.
Currently there is no a simple way to reliably detect and predict
which patients will develop bone metastasis. The detection of bone
metastases relies on imaging technology, but novel approaches
based on biomarker assessments are under intense investigation.
Increasing body of data suggests that metastatic dissemination is
site specific (Horak and Steeg, 2005) and that distinct molecular
factors regulate bone metastasis formation (Yin et al, 2005). A
multifactorial and multistep process of bone metastasis formation
involves several biological mechanisms including angiogenesis,
invasion through extracellular matrix degradation, osteoblast/
osteoclast activation and bone remodeling activity (Guise and
Mundy 1998). Angiogenesis or blood vessel formation occurs in
both physiological and pathological conditions, such as metastatic
formation (Liotta et al, 1991; Folkman, 2003). Molecular factors
regulating angiogenesis have been found also implicated in the
regulation of tumour invasion (Kalebic et al, 1983). The number
and density of microvessels in different human cancers was found
associated with their invasive and metastatic potential (Kato et al,
2003) and have been shown to correlate with the serum
concentrations of angiogenic factors such as the vascular
endothelial growth factor (VEGF) (Coskun et al, 2003). High
circulating levels of VEGF have been found to correlate with more
advanced stages or with a worse prognosis in different tumours
and in particular in women with breast cancer (Linderholm et al,
2000). Histological studies of bone metastases show that tumour
cells remain in the bone marrow cavity and secrete factors that
regulate bone cells including parathyroid hormone related protein
(PTHrP), tumour necrosis factor (TNF), interleukin-6 (IL-6) and
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stransforming growth factor (TGF)b (Yin et al, 2005). Among these
local factors, serum TGFb was recently shown to be associated with
disease progression and poor prognosis in patients with metastatic
breast cancer (Cui et al, 1996; Sheen-Chen et al 2001; Ivanovic
et al, 2003). Matrix-metalloproteases (MMPs) are a family of zinc-
dependent endopeptidases, which degrade the extracellular matrix
proteins. Increased levels of MMPs have been found associated
with basement membrane invasion, which plays an important role
in metastasis formation (Kalebic et al, 1983; Stetler-Stevenson,
1994, 1995; Kleiner and Stetler-Stevenson, 1999). The activity of
MMPs is regulated by tissue inhibitors (TIMPs) (Chenard et al,
1996; Duffy et al, 2000; Hirvonen et al, 2003). Among the different
MMPs, it has been shown that increased expression of MMP-2 was
associated with early relapse and short survival (Talvensaari-
Mattila et al, 1998; Talvensaari-Mattila et al, 1999). The coexpres-
sion of MMP-2 and MMP-9 provided unfavourable prognostic
value in node-negative breast cancer patients (Li et al, 2004).
Bone metastases from breast cancer induce alterations of bone
remodelling activity mediated by cytokines and growth factors
secreted in the bone microenvironment by cancer cells. Increased
osteoclastic bone resorption is likely to play a major role in mainly
lytic features of bone metastases process. The pivotal regulator of
osteoclastic activity is the system osteoprotegerin (OPG)/receptor
activator of NF-kB (RANK)/RANK-ligand (RANKL) (Hofbauer
et al, 2004), which is involved in physiological as well as
pathological conditions, such as metastatic bone disease and
multiple myeloma (Chikatsu et al, 2000; Lipton et al, 2002; Park
et al, 2003; Vanderkerken et al, 2003). Increase levels of OPG but
not RANKL have also been reported in patients with prostate
cancer and bone metastases (Jung et al, 2004).
The markers of bone turnover, which include enzymes
predominantly expressed by the osteoblasts, such as bone alkaline
phosphatase (bone ALP), and osteoclasts – such as the tartrate
resistant acid phosphatase, (TRACP) – or bone matrix synthesis
and degradation products (Fontana et al, 1999) have demonstrated
increased serum and urine levels in patients with bone metastases
(Demers et al, 2000). Our previous study has shown that bone
matrix degradation markers especially the type I collagen C-
telopeptides fragments CTX and ICTP, which reflect cathepsin K-
and MMP-mediated type I collagen degradation, respectively,
could be useful in monitoring bone metastasis (Garnero et al,
2003a).
Most of the previous studies evaluated only one or a few of the
above described biochemical markers in cancer patients. Those
markers were usually linked to a particular biological process and
the sensitivity to detect bone metastases was rather limited. The
aim of our study was to measure a panel of systemic biochemical
markers associated with multiple biological processes involved in
the formation of bone metastases. We have assessed those markers
in patients with the primary breast carcinoma with or without
bone metastases and investigated whether a combination of
markers could be used as a novel tool to detect and predict bone
metastasis in breast carcinoma patients.
MATERIALS AND METHODS
Patients
Fasting morning serum samples from patients with breast
carcinoma (BC) and healthy age-matched women were provided
by ASTERANG (Detroit, USA) and Clinomics Biosciences (New
York, NY, USA), respectively. All serum samples were kept frozen
at  701C until conducting the assay. All subjects gave written
informed consent to participate in the study, which was carried out
in accordance with the Helsinki declaration. The main character-
istics of patients with and without bone metastases with respect to
tumour size, stage, tumour histology, nodal status, oestrogen
receptor (ER) status and therapy are shown on Table 1.
The following groups of patients were investigated in cross-
sectional and longitudinal analyses
Crossectional study
  Twenty-nine postmenopausal women with primary breast
cancer without bone metastases were included. The majority
of patients presented with infiltrating ductal carcinoma. Bone
survey with Tc-99 bone scan and X-ray showed no bone
metastases. Patients were also free of nonbone metastases.
  Twenty-eight postmenopausal women with primary breast
cancer and radiologically confirmed bone metastases. The
majority of patients presented with infiltrating ductal carcino-
ma. Among these patients 4 (14%) had also lung metastases.
  Fifteen healthy postmenopausal women (mean age: 5976 years)
with no history of breast disease or metabolic bone disease.
Longitudinal study
  Thirty-four postmenopausal women with breast cancer without
bone metastases at the time of diagnosis were followed for a
median of 3 years (1–6 years). Bone scintigraphy was
performed every 3–6 months in all patients to monitor
appearance of bone metastases. Among these 34 patients, 19
patients remained free of bone whereas the other 15 developed
bone metastases.
Table 1 Characteristics of women with breast cancer and without bone
metastases
Characteristics
Patients with
primary breast
cancer n¼29
Patients with
breast cancer and
bone metastases
n¼28
Age (mean, s.d.); year 53, 10 55, 11
Weight (mean, s.d.), kg 65.4, 11.3 69.4, 11.7
Height (mean, s.d.), cm 164, 5.6 160, 10.9
Tumour size (%)
T1 69 50
T2 28 29
T3 0 7
T4 0 11
Unknown 3 3
Stage (%)
I9 3 1 1
II 7 32
III 0 3
IV 0 54
Histology (%)
Ductal carcinoma 58 64
Lobular carcinoma 7 7
Other 14 7
Unknown 21 22
Axillary nodal status (%)
N– 97 64
N+ 3 36
Oestrogen receptor
positivity (%)
52 82
Therapy (%)
Radiation 16 0
Chemotherapy 21 22
Hormonal 0 22
Unknown 63 56
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s  In the 19 patients who remained free of bone metastases, the
second samples were obtained after 3 years in 14 of the patients
and after 6 years in the others. During this period, none of these
patients developed nonbone metastases. At the time of first
sampling, four (21%) received chemotherapy, three (16%) had
radiotherapy and information on treatment was not available in
the rest.
  For patients who developed bone metastases, the second sample
was obtained before bone metastases were documented by bone
scans. The delay between the second measurement and
diagnosis of bone metastases on bone scan was 1 month for
nine patients, 2 months for two patients, 4 months for two
patients and 6 months for two patients.
  None of these patients developed nonbone metastases. At the
time of first sampling, four (27%) received chemotherapy, four
(27%) hormonal treatments and information on treatment was
not available in the rest.
Biochemical markers
Growth factors Serum VEGF was measured by an ELISA
recognising both VEGF165 and VEGF121 isoforms (Quantikine
s
R&D, Minneapolis, USA). The intra and inter assay precision
errors are 7 and 8%, respectively. Serum TGFb1 was measured by a
two site ELISA using specific antibodies raised against human
recombinant TGFb1 (IBL, Hamburg Germany). The intra and inter
assay precision error are below 1.4 and 11%, respectively.
Osteoclastogenesis markers Serum OPG was measured by a two
site immunoassay using antibodies raised against recombinant
human OPG (Biomedica, Vienna, Austria). Intra and inter assay
variations are lower than 10 and 13%, respectively. Serum RANK-L
was measured by an immunoassay based on a sandwich between
coated OPG and a polyclonal antibody raised against recombinant
human RANK-L (Biomedica, Vienna, Austria). The intra- and
inter-assay variation are lower than 10%.
Matrix-metalloproteases Serum MMP 2, 7 and 9 were measured
by two site ELISAs (Quantikine
s R&D, Minneapolis, USA). The
intra- and inter-assay precision errors are 2 and 8 % for MMP-2,
2.2 and 6%, for MMP-7 and 7 and 11%, for MMP-9. Serum TIMP-1
was measured by a two site ELISA using specific antibodies
raised against human recombinant TIMP-1 (Quantikine
s R&D,
Minneapolis, USA). The intra and inter assay precision errors are
below 3 and 10%, respectively.
Bone turnover markers
Bone formation markers Serum bone ALP was measured by an
immunochimiluminescence assay using the Ostase reagent on an
automatic analyzer (Ostase, Access, Beckman Coulter, Fullerton,
CA, USA). The intra and inter assay CV are below 3.5 and 8%,
respectively. The cross-reactivity of the assay with the liver
isoenzyme is of 13%. Serum intact procollagen type I N propeptide
(PINP) was measured with a two site immunoassay based on
monoclonal antibodies raised against purified intact human PINP
and detecting both intact mono and trimeric forms, but not
fragments using an automated analyzer (Elecsys, Roche Diagnos-
tics, Mannheim, Germany). Intra-assay variation is lower than 3%
and inter-assay variation lower than 4%.
Bone resorption markers Serum C terminal crosslinking telopep-
tide of type I collagen (S-CTX) was measured by a two site assay
using monoclonal antibodies raised against an eight amino-acid
sequence from the C-telopeptide of human type I collagen by
an automatic analyzer (Elecsys, Roche Diagnostic, Mannheim,
Germany). Intra-assay variation is lower than 3% and inter-assay
variation is lower than 5%. Serum C-terminal crosslinking
telopeptide of type I collagen generated by MMPs (ICTP) was
measured by a radioimmunoassay (Telopeptide ICTP, Orion
Diagnostica, Espoo, Finland). The intra- and inter-assay CVS are
below 5 and 7%, respectively. Serum TRACP isoform 5b (TRACP
5b) was measured by a specific immunoassay using a monoclonal
antibody raised against TRACP 5b purified from human osteo-
clasts and recombinant human TRACP5b as a standard (SBA
Sciences, Turku, Finland). Intra- and inter-assay coefficients of
variation are lower than 10%.
Statistical analysis
Statistical analyses were performed using the Statistical Analysis
System 8e (SAS Institute Inc., Cary, NC, USA). Differences of
biochemical marker levels between patient groups were analysed
using the nonparametric Kruskal–Wallis test, followed by Mann–
Whitney or Wilcoxon tests for two-group comparisons. Relation-
ships between biochemical markers were assessed using the
Spearman (rank) correlation analysis. Diagnostic accuracy was
evaluated by receiving operating curve (ROC) analysis. Sensitivity
and specificity to detect bone metastases were calculated using the
cutoff level with the highest diagnostic accuracy obtained from
ROC analysis. Diagnostic accuracy was calculated as the propor-
tion of patients with (true positive) or without (true negative) bone
metastases correctly classified.
A discriminant analysis was performed to determine the optimal
combination of biochemical markers to distinguish patients with
and without bone metastases. In this model, biomarkers were used
as quantitative continuous variables and the two groups (with or
without metastases) as a dichotomous classification variable. A
stepwise discriminant analysis (stepwise backward elimination)
was performed to select a subset of the quantitative continuous
variables for use in classifying patients between the two groups.
The significance level allowing to the markers not to be excluded
from the model was 0.15.
Under the hypothesis of a multivariate normal distribution
within each group, the discriminant function was determined by a
measure of generalised squared distance. A performance of the
discriminant criterion was evaluated by estimating error rates in
the classification of future observations.
In longitudinal analysis, for each patient the changes during
follow-up in biochemical marker levels were calculated as ((follow-
up value baseline value)/baseline value) adjusted for the time of
follow-up. Baseline and changes in biochemical markers between
patients who developed and those who did not develop bone
metastases during follow were compared using nonparametric
Mann–Whitney test.
RESULTS
Levels of biochemical markers of angiogenesis,
osteoclastogenesis and bone turnover in breast carcinoma
patients with and without bone metastases
All biochemical markers were significantly increased in patients
with breast cancer with bone metastases, when compared to either
the patients with breast cancer without bone metastases or healthy
controls, except for TGFb1 levels, which were significantly
decreased (P¼0.05 and P¼0.005, respectively) (Figures 1–3).
In contrast, patients with breast cancer without bone metastases
and healthy controls have shown a comparable level of biomarkers.
However, slightly lower levels of TGFb1( Po0.0001) and MMP-2
(P¼0.03) and a small increase of MMP-9 (P¼0.001), OPG
(P¼0.003) and CTX (P¼0.0007) have been detected in breast
carcinoma patients (Figures 1–3).
No significant difference among three groups in serum RANK-L
(data not shown) has been observed. These data need to be
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sinterpreted with caution because the number of undetectable
values was high (13, 79 and 33% in healthy controls, patients with
breast cancer and without bone metastases, patients with breast
cancer and with bone metastases, respectively), and this marker
was no considered in the subsequent statistical analyses.
Relationships between biochemical markers
In women with breast cancer, there were significant correlations
between all bone turnover markers (r values ranging from 0.26 to
0.78, Po0.05–0.0001). Interestingly, among the two type I collagen
degradation markers, ICTP showed higher associations with VEGF
(r¼0.37, Po0.01), MMP-2 (r¼0.68, Po0.0001) (Figure 4), MMP-
7( r¼0.53, Po0.0001), TIMP-1 (r¼0.63, Po0.0001), Bone ALP
(r¼0.71, Po0.0001), PINP (r¼0.66, Po0.0001), TRACP5b
(r¼0.60, Po0.0001) and OPG (r¼0.26, Po0.05) than CTX which
demonstrated no significant association with VEGF and OPG, and
only weak association with the other markers (r¼0.26–0.78,
Po0.05–0.0001). VEGF correlated weakly with MMP-2 and -7 and
was highly associated with TIMP-1 (Po0.0001).
TGFb only weakly correlated with MMP-2, TIMP-1 and
TRACP5b (Po0.01). OPG did not significantly correlated with
the other markers, except slightly with MMP-9 (r¼0.33, Po0.05)
and TIMP-1 (r¼0.45, Po0.001).
Sensitivity and specificity of biochemical markers for
detecting bone metastases
To investigate the diagnostic value of the biochemical markers to
distinguish patients with breast cancer with and without bone
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smetastases, ROC analyses were performed. As shown in Table 2, at
the optimal cutoff value each marker had a similar diagnostic
sensitivity with about 68–83% of patients correctly classified with
or without bone metastases, except for TGFb1 and OPG, which
demonstrated low sensitivity and specificity and a diagnostic value
lower than 65% (Table 2). For most of the markers, the optimal
cutoff which discriminates between patients with and without bone
metastases is comparable to the upper limit of healthy controls as
defined by the 95th percentile (Table 2).
When all markers were included in a multivariable discriminant
analysis model, TRACP5b (P¼0.009), CTX (P¼0.03), VEGF
(P¼0.05) and ICTP (P¼0.14) were significantly and indepen-
dently associated with the presence of bone metastases. In this
analysis, markers were included in the model when the associated
P-value is o0.15 (see Materials and methods). This combination of
markers allowed to correctly classifying 85% of patients with or
without bone metastases.
Biochemical markers and progression toward bone
metastases
To investigate whether biochemical markers could predict which
patients are at risk for developing bone metastases, patients with a
primary breast cancer who did and did not progress toward bone
metastases during follow-up have been compared.
As shown on Table 3, at the time of primary breast cancer, there
was no statistical significant difference in any biochemical markers
between patients who did and those who did not progress toward
bone metastases. Serum TRACP5b levels were on average 95%
higher in patients who will develop bone metastases compared to
levels in patients who did not develop bone metastases although
the difference did not reach statistical significance (P¼0.08).
During the follow-up period, levels of all markers increased
significantly in patients who developed bone metastases before
they were documented by bone scan, except for PINP and CTX
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s(Figure 5). The percentage of patients with values above the upper
limit of controls was low at the time of diagnosis of primary breast
cancer and increased in those patients who developed bone
metastases for all markers except CTX-I (Figure 6). For patients
who did not develop bone metastases all markers also increased
significantly, except for OPG and CTX. The increase in the
biochemical markers was higher in patients who progressed
toward bone metastases when compared to those who did not,
although the difference reached statistical significance only for
MMP-7, TIMP-1 and ICTP and was borderline significant for bone
ALP (Figure 5).
DISCUSSION
This is one of the few studies which investigated a broad panel of
biochemical markers reflecting the multiple biological processes
involved in the formation of bone metastases associated with
breast cancer. We investigated the association of these markers
with bone metastases both in cross-sectional and longitudinal
analysis. We found that biochemical markers of angiogenesis
(VEGF), degradation of extracellular matrices (MMPs) and bone
resorption were positively associated with bone metastases in
breast carcinoma patients. Moreover, our data suggest that a few
of these markers could be of clinical usefulness, since they have
shown independent predictive value.
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Figure 4 Correlation between serum MMP-2 and serum ICTP in
patients with breast cancer with or without bone metastases included in
the cross-sectional analysis.
Table 2 Diagnostic value of biochemical markers to distinguish breast carcinoma patients with bone metastases from those without bone involvement
Marker Cutoff value AUC
Sensitivity
(%)
Specificity
(%)
Diagnostic
accuracy (%)
95th Percentile of
healthy controls
VEGF (pg/ml) 478 0.768 43 100 78 202
TGb1 (ng/ml) 41 0.511 18 95 65 39.8
MMP-2 (ng/ml) 169 0.900 83 85 85 174
MMP-7 (ng/ml) 4.62 0.752 43 98 76 3.41
MMP-9 (ng/ml) 376 0.702 79 66 71 144
TIMP-1 (ng/ml) 176 0.768 46 91 74 149
Bone ALP (ng/ml) 11.5 0.858 79 82 81 9.6
PINP (ng/ml) 80 0.815 46 98 78 79
TRACP 5b (U/l) 3.05 0.856 64 95 83 2.87
OPG (pmol/l) 5.33 0.600 32 84 64 3.67
CTX (ng/ml) 0.382 0.814 95 75 68 0.353
ICTP (mg/l) 4.47 0.903 86 82 83 4.25
Receiving operating curves (ROC) were generated and the area under the curve (AUC) sensitivity, specificity were determining at the cutoff providing the highest diagnostic
accuracy for each individual marker.
Table 3 Levels of biochemical markers at the time of diagnosis of
primary breast carcinoma in patients who developed and in those who
remained free of bone metastases during the following 3 years
Bone metastases at baseline
Marker Yes (n¼15) No (n¼19) P-value
VEGF (pg/ml) 114 (242) 160 (154) 0.61
TGFb1 (ng/ml) 29.1 (10.2) 30.5 (8.0) 0.16
MMP-2 (ng/ml) 121 (97) 116 (63 0.39
MMP-7 (ng/ml) 1.8 (1.1) 2.5 (1.1) 0.06
MMP-9 (ng/ml) 127 (210) 226 (188) 0.14
TIMP-1 (ng/ml) 87 (80) 106 (58.9) 0.11
Bone ALP (ng/ml) 8.2 (8.5) 8.3 (6.6) 0.60
PINP (ng/ml) 47 (24) 30 (27) 0.20
TRACP5b (U/l) 3.7 (2.1) 1.9 (1.3) 0.08
OPG (pmol/l) 3.1 (1.4) 3.0 (2.5) 0.91
CTX (ng/ml) 0.2 (0.3) 0.2 (0.1) 0.57
ICTP (mg/l) 3.1 (2.2) 3.2 (1.3) 0.78
Data are expressed as median (interquartile).
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changes between the two groups. *Po0.05, **Po0.01, ***Po0.001 at
follow-up vs baseline in each group separately.
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metastases, but not in patients with a localised disease, which is
consistent with previous studies (Adams et al, 2000; Coskun et al,
2003). Increased VEGF level was also associated with biochemical
markers of osteoclastic activity and bone matrix degradation,
which is in agreement with a recent study showing high that VEGF
stimulates osteoclastic differentiation in vitro (Aldridge et al,
2005).
Our study investigated for the first time the serum levels of
TGFb1 in patients with and without bone metastasis and identified
that both breast cancer patients with and without bone metastases
had significantly lower levels compared to healthy age-matched
controls. Decreased TGFb levels in breast carcinoma patients is
consistent with the inhibitory effect of endogenous TGFb on
human breast cancer cells proliferation (Zugmaier et al, 1989;
Arteaga et al, 1990). Other studies, however, have reported no
significant difference of serum TGFb1 levels between breast cancer
patients and healthy controls, indicating a need for further
examination in larger studies (Sheen-Chen et al, 2001; Ivanovic
et al, 2003; Lebrecht et al, 2004).
The role of MMPs in breast cancer initiation, invasion and
metastasis is well established (Kleiner and Stetler-Stevenson, 1999;
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Figure 6 Individual values of biochemical markers of angiogenesis, tumour invasion and bone turnover in the 15 patients participating in the longitudinal
evaluation who develop bone metastases during follow-up. For each marker, individual values are shown at the time of diagnosis of primary breast cancer
(baseline) and at the time of second sampling before bone metastases was documented by bone scan (follow-up, see Patients and methods). Dotted lines
indicate the upper limit of healthy controls (95th percentiles); the percentages represent the proportion of patients with values above the upper limit of
healthy controls at baseline and at follow-up.
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sDuffy et al, 2000). MMP-9 has been found to be associated with
poor prognosis and metastatic potential of breast carcinoma
(Duffy et al, 1995). Similarly, high serum level of MMP-2 indicated
adverse prognosis in node-positive breast carcinoma (Leppa et al,
2004). Our data confirm the involvement of MMP-2 and MMP-9 in
promoting bone metastases. This is the first study showing a slight
increase of circulating levels of MMP-7 in patients with breast
cancer and bone metastases. Interestingly, a recent immunohis-
tochemistry study has reported expression of MMP-7 in about 50%
of human breast cancer cells which correlates with tumour
invasion (Mylona et al, 2005).
Osteoprotegerin, a pivotal regulator of the osteoclastic activity,
(Hofbauer and Schoppet, 2004) has been found to be increased in
prostate cancer patients with bone metastases – but not in those
with localised diseases (Brown et al, 2001; Jung et al, 2004). In our
study, breast cancer patients with or without bone metastases had
increased OPG levels compared to healthy controls, contrasting
with the absence of elevation found by Lipton et al (2002). The
reasons for these discrepancies are unclear, but they could be
attributed to patient population characteristics and/or specificity
of assays for the various circulating forms of OPG (Yano et al, 1999).
To assess bone formation and bone resorption, we measured the
currently available most sensitive and specific biochemical
markers (Garnero and Delmas, 2003). For formation, we assessed
serum bone ALP, a specific enzyme of the osteoblastic cells and
serum PINP, which reflects the synthesis of the main bone matrix
protein. For bone resorption, we evaluated serum TRAPC5b a
specific enzyme of the osteoclastic cells, and serum CTX and ICTP,
two fragments of type I collagen degradation. Previous studies
have evaluated only a few of these markers (Fohr et al, 2003), but
our study is one of the first which measured concomitantly all of
them in the same patients. We found that ICTP and CTX were only
modestly associated and ICTP – but not CTX – was highly
correlated with MMPs, in particular, MMP-2. These findings
suggest that in patients with metastatic bone disease, serum CTX
and ICTP could reflect distinct biological pathways of bone
resorption, consistent with in vitro studies showing that ICTP –
but not CTX – is directly released from bone collagen matrix by
MMPs, while CTX could be released from bone collagen by other
proteolytic enzymes, such as cathepsin K (Garnero et al, 2003b).
To assess the potential clinical usefulness of biochemical
markers, we have determined their sensitivity, specificity and
accuracy to distinguish patients with and without bone metastases.
At the optimal cutoff value determined from ROC analyses, we
found that each marker has a similar diagnostic accuracy except
for TGFb1 and OPG, which demonstrated very low sensitivity. It is
difficult to compare the cutoff values we determined in this study
with previous reports because these are highly dependent on the
actual assay used which can differ between studies for a same
marker and which are not standardised. Interestingly, however, the
optimal cutoff values determined by ROC analyses were very close
to the upper limit of healthy controls for most markers. Thus, if
confirmed in other larger studies, using the 95th percentile of
healthy age-matched could represent an adequate cutoff to best
differentiate patients with breast cancer with or without bone
metastases. In multivariable analyses, we found that besides
markers of bone resorption, which are specific to bone, only
VEGF was independently associated with bone metastases,
probably because it mediates biological processes involved at
multiple steps of bone metastasis formation.
Very few studies have investigated whether biochemical markers
measured in patient with primary breast cancer could predict the
development of bone metastasis. In a study of 388 patients with
localised breast cancer, Diel et al (1999) reported that breast
carcinoma patients with increased level of bone sialoprotein (BSP)
were at a higher risk of devolving bone metastases over the
following 20 months. More recently, in a small case–control study,
Seibel et al (2002) found no difference in several biochemical
markers of bone turnover including bone ALP, osteocalcin, PICP,
serum CTX and the urinary excretion of deoxypyridinoline
between the 11 patients who developed bone metastases and the
44 controls. That study, however did not investigate serum
TRACP5b and ICTP. Among the markers we evaluated in our
study, only TRACP5b was increased in patients with a primary
carcinoma who progressed toward bone metastases, when
compared to patients who did not develop bone metastasis.
However, the difference did not reach statistical significance,
probably because of the limited number of subject we evaluated.
Interestingly, during follow-up serum MMP-7, TIMP-1 and ICTP
increased even before bone metastases could be documented by
bone scans. If confirmed in larger prospective studies, these
findings suggest that biochemical abnormalities may be detected
by serum tests before bone metastases are being documented by
bone scintigraphy.
In conclusion, this cross-sectional and longitudinal evaluation of
multiple circulating biochemical markers reflecting the different
biological processes involved in bone metastases development
indicate that markers of bone resorption were the most sensitive to
detect the presence of bone metastasis in breast cancer patients.
If confirmed in larger prospective studies, regular monitoring of
patients with primary breast cancer by an optimal combination of
circulating biochemical markers may allow detecting individuals
with bone metastases at an early stage, potentially before detection
with bone scintigraphy.
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